The FDA has signed off on a Phase 3 clinical trial evaluating Humanigen’s (OTCQB:HGEN)
lenzilumab, its Humaneered anti-human GM-CSF monoclonal antibody, for
the prevention of respiratory failure and/or death in hospitalized
COVID-19 patients with pneumonia.
The company says it is the only one that it working on preventing cytokine storm via GM-CSF neutralization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.